/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

H

Hrishikesh K. Srinagesh

Stanford University(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

80

Papers

612

Citations

10

h-index

10

i10-index

Hrishikesh K. Srinagesh is an academic researcher from Stanford University. The author has contributed to research in topics: CAR-T cell therapy research & Immune Cell Function and Interaction & Autoimmune and Inflammatory Disorders Research. The author has an h-index of 10, co-authored 68 publications.

ORCID: 0000-0001-9786-3010

Research Topics

CAR-T cell therapy research Immune Cell Function and Interaction Autoimmune and Inflammatory Disorders Research Immunodeficiency and Autoimmune Disorders Biosimilars and Bioanalytical Methods

Papers by this author

works

CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study

2024 · The Lancet · 47 citations

https://doi.org/10.1016/s0140-6736(24)00746-3

Matthew J. Frank John H. Baird Anne Marijn Kramer Hrishikesh K. Srinagesh

MAGIC biomarkers of acute graft-versus-host disease: Biology and clinical application

2019 · Best Practice & Research Clinical Haematology · 26 citations

https://doi.org/10.1016/j.beha.2019.101111

Hrishikesh K. Srinagesh James L.M. Ferrara

A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

2024 · Transplantation and Cellular Therapy · 10 citations

https://doi.org/10.1016/j.jtct.2024.03.022

Muna Qayed Urvi Kapoor Scott Gillespie Adrianna Westbrook

Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL

2025 · Cancer Discovery · 3 citations

https://doi.org/10.1158/2159-8290.cd-24-1071

Yi‐Jiun Su Anne Marijn Kramer Mark P. Hamilton Neha Agarwal

Figure S9 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL

2025 · 0 citations

https://doi.org/10.1158/2159-8290.28713417

Yi‐Jiun Su Anne Marijn Kramer Mark P. Hamilton Neha Agarwal

Table S3 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL

2025 · 0 citations

https://doi.org/10.1158/2159-8290.28713408

Yi‐Jiun Su Anne Marijn Kramer Mark P. Hamilton Neha Agarwal

Research topics

topics

CAR-T cell therapy research

Immune Cell Function and Interaction

Autoimmune and Inflammatory Disorders Research

Immunodeficiency and Autoimmune Disorders

Biosimilars and Bioanalytical Methods

Chat about Author

Papers

Chat

Click to start Chat